Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Radiation Oncology, Tenon University Hospital, Hôpitaux Universitaires Est Parisien, Sorbonne University, Paris, France.
Int J Radiat Oncol Biol Phys. 2021 Aug 1;110(5):1396-1406. doi: 10.1016/j.ijrobp.2021.02.053. Epub 2021 Mar 5.
To evaluate the feasibility and efficacy of involved-field irradiation in definitive chemoradiation therapy for locoregional esophageal squamous cell carcinoma.
Patterns in recurrence and elective nodal failure were analyzed in patients from the previously published ESO-Shanghai 1 trial, who received definitive chemoradiation therapy with involved-field irradiation to 61.2 Gy in 34 fractions using intensity modulated radiation therapy planning. Nodal regions were delineated using the lymph node map from the sixth edition of the American Joint Committee on Cancer staging system. Elective nodal failure was defined as recurrence in the regional nodal area outside the planning target volume. Extensive elective nodal failure, defined as an extensive nodal area regardless of tumor location, was calculated for additional analysis. The incidental (ie, mean) irradiation dose of each node and each region was evaluated.
With a median follow-up of 48.7 months among survivors, the 3-year actuarial rate for overall survival was 53.6%, and the median overall survival was 44.8 months (95% confidence interval, 34.6-55.0). Of the 436 patients included in this study, 258 patients (59.2%) experienced treatment failure. Elective nodal failure was experienced by 37 patients (8.5%), 7 (1.6%) of whom encountered nodal-only failure. The 3-year actuarial rates of elective nodal control and elective nodal-only control were 89.7% and 97.9%, respectively. The median incidental dose of these nodes was 33.2 Gy (interquartile range [IQR], 1.3-50.7 Gy). The median distance of each node to the planning target volume was 1.4 cm (IQR, 0.6-4.9 cm). Extensive elective nodal failure was experienced by 51 patients (11.6%), and 20 (4.6%) patients had nodal-only failure. The 3-year extensive elective nodal control and extensive elective nodal control-only rates were 86.0% and 94.3%, respectively. The median incidental dose of these nodes was 23.2 Gy (IQR, 1.1-53.5 Gy). The median distance of each node to the planning target volume was 2.0 cm (IQR, 0.6-5.5 cm).
Involved-field irradiation can achieve a low rate of isolated nodal failure and a satisfactory survival outcome. The use of elective nodal irradiation may be unnecessary in definitive chemoradiation therapy for the treatment of locoregional esophageal squamous cell carcinoma.
评估累及野照射在局部区域食管鳞癌根治性放化疗中的可行性和疗效。
对先前发表的 ESO-Shanghai 1 试验中的患者进行了复发和选择性淋巴结失败模式分析,这些患者接受了根治性放化疗,采用调强放疗计划给予 61.2Gy/34 次的累及野照射。淋巴结区域采用美国癌症联合委员会第六版分期系统的淋巴结图谱进行划定。选择性淋巴结失败定义为计划靶区外区域淋巴结的复发。为了进行额外的分析,定义了广泛的选择性淋巴结失败,即无论肿瘤位置如何,广泛的淋巴结区域。评估了每个淋巴结和每个区域的意外(即平均)照射剂量。
在生存者中,中位随访时间为 48.7 个月,总生存的 3 年估计率为 53.6%,中位总生存时间为 44.8 个月(95%置信区间,34.6-55.0)。在本研究中纳入的 436 例患者中,258 例(59.2%)患者发生了治疗失败。37 例(8.5%)患者发生了选择性淋巴结失败,其中 7 例(1.6%)患者仅发生了淋巴结失败。选择性淋巴结控制和选择性淋巴结控制的 3 年估计率分别为 89.7%和 97.9%。这些淋巴结的中位意外剂量为 33.2Gy(四分位距[IQR],1.3-50.7Gy)。每个淋巴结与计划靶区的中位距离为 1.4cm(IQR,0.6-4.9cm)。51 例(11.6%)患者发生广泛选择性淋巴结失败,20 例(4.6%)患者仅发生淋巴结失败。广泛选择性淋巴结控制和广泛选择性淋巴结控制仅有的 3 年估计率分别为 86.0%和 94.3%。这些淋巴结的中位意外剂量为 23.2Gy(IQR,1.1-53.5Gy)。每个淋巴结与计划靶区的中位距离为 2.0cm(IQR,0.6-5.5cm)。
累及野照射可实现低孤立淋巴结失败率和满意的生存结果。在局部区域食管鳞癌的根治性放化疗中,选择性淋巴结照射可能是不必要的。